News
3 High-Yield Healthcare Stocks
Picking solid high-yield dividend stocks can be tricky. Most companies that offer an elevated yield, after all, tend to do so because of a fundamental weakness in their underlying business. Our....
Here's Why Alnylam Pharmaceuticals Rallied 32.7% in September
Powered by encouraging phase 3 results for an important pipeline drug, shares of clinical-stage biotech Alnlyam Pharmaceuticals (NASDAQ: ALNY) , which focuses on RNAi treatments, gained 33% in....
Why Regeneron Pharmaceuticals Dropped 11.3% in September
Despite sharing a series of positive news items with investors, shares of biotech-giant Regeneron Pharmaceuticals (NASDAQ: REGN) fell more than 11% in September, according to data from S&P....
3 High-Yield International Stocks
Most investors fail to look beyond their home country's borders for investment opportunities. That's a shame because great businesses can be found all around the world.Want proof? We asked a team....
5 Numbers That Should Get MannKind Investors Excited
MannKind (NASDAQ: MNKD) hasn't exactly given investors a whole lot to get excited about in recent years. That could be changing, though. Since May, MannKind stock has soared more than 130% and now....
Why Novavax, Inc. Could Be a Gold Mine for Growth Investors
If you had the misfortune to buy Novavax (NASDAQ: NVAX) stock in July 2015 and held on, around 90% of your investment would have been wiped out. Ouch. Even if you had bought the biotech stock at....
3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?
One great thing about the biotech industry is that there are nearly always some winners. Regardless of what's going on in the world or in the broader market, at least a few biotech stocks are....
Alnylam Notches a Game-Changing RNAi Win
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is researching therapies that can treat genetic diseases by interfering with gene expression. Though Alnylam has yet to validate its approach with a....
Gilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors
The year 2021 -- that's when Gilead Sciences (NASDAQ: GILD) thinks its acquisition of Kite Pharma (NASDAQ: KITE) will start to pay off. When Gilead announced plans to buy Kite, the company stated....
Why Lexicon Pharmaceuticals Is Down 11% Today
After Lexicon Pharmaceuticals (NASDAQ: LXRX) announced yesterday the publication of phase 3 results for its lead diabetes drug, sotagliflozin, in the New England Journal of Medicine, its shares....
5 Things Regeneron's CEO Said as the Biotech Stock Sank
Regeneron (NASDAQ: REGN) CEO Leonard Schleifer was on the hot seat Monday at the Morgan Stanley healthcare conference. And the timing was either terrific or terrible, depending on your....
Is Amicus Therapeutics Stock Still a Strong Buy?
According to data from S&P Global Market Intelligence, shares of rare-disease drugmaker Amicus Therapeutics (NASDAQ: FOLD) rose by 6.6% last month. Although the company did provide a bevy of....
3 Things Total SA's Management Thinks You Should Know
So far in 2017, Total's (NYSE: TOT) management team has made the pivot from preserving capital to growing the business with several new project announcements and joint venture deals. The knee jerk
The Hidden Gem in Novavax's Pipeline You'll Want to Watch
If you've looked into Novavax (NASDAQ: NVAX), you know the clinical-stage biotech's primary focus is on its experimental RSV F vaccine. Novavax has had its fair share of ups and downs with that
Novo Nordisk A/S Continues Its Comeback
Novo Nordisk (NYSE: NVO) released earnings for the first half of 2017, and while revenue growth wasn't spectacular, considering how last year went for the diabetes specialist, investors will take it.M
Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals: Which Company Reported Better Earnings
Vertex Pharmaceuticals (NASDAQ: VRTX) and Regeneron Pharmaceuticals (NASDAQ: REGN) are two big-cap biotech stocks, and each recently reported second-quarter financial results that were better than
Why Shares of ImmunoGen Inc. Shot Up Today
ImmunoGen (NASDAQ: IMGN) ended Friday up 14% after reporting second-quarter earnings earlier in the day. Of course, it wasn't the cancer-focused biotech's earnings that caused shares to jump by double
Total SA Plans to Open Up the Checkbook After Impressive Q2 Earnings
It was pretty much a foregone conclusion that eventually oil and gas companies were going to start spending more money on exploration and development of new sources. The amount of underinvestment is
3 Stocks That Could Be Life-Changers
As the saying goes, "If there's no risk, there's no reward." No investment is without risk, but stocks that have life-changing potential tend to come with higher risks than your average investment. Of
EUR/USD – Bundeskanzlerin Merkel gibt EZB und Ölpreis die Schuld!
Lieber Leser,
der EUR/USD kann sich am Donnerstag von seiner leichten Korrektur wieder lösen und nimmt Fahrt in Richtung 1,1250 US-Dollar je Euro auf. Wir haben zuvor argumentiert, dass die....
Michelin SCpA. – Käufer zeihen sich schlagartig zurück, Short-Chance!
Liebe Trader,
Bereits seit Anfang 2009 tendiert das Wertpapier des Reifenherstellers Compagnie Generale des Etablissements Michelin in einer ungebrochenen Aufwärtsbewegung und konnte sich von....
Société Générale: Wie wär`s mit einem Trade auf die Frankreich-Wahl!
Liebe Leser,
Bisher gehen alle Meinungsforscher davon aus, dass Emmanuel Macron das Rennen am Sonntag macht und wir schließen uns dieser Meinung an. Für einen Trade auf diesen Ausgang der Wahl....
Axa: Das hat funktioniert!
Liebe Leser,
erfreuliche News gab es in der letzten Woche bei Axa, denn Rudolf Markus Schug hatte über die entsprechenden Trading-Chancen informiert.
Trade-Vorschlag! Am 13. April hatten wir den....
EDF: Steht dieser Energie-Riese vor einer strahlenden Zukunft?
Liebe Leser,
es gibt Konzerne, die haben ihren Ruf weg; so auch der französische Versorger-Konzern Electricité de France (EDF): „Zu viel Atomkraft, so unflexibel“, heißt es oft im Zusammenhang mit....
Axa: Volltreffer! Vielen Dank an die Franzosen für 65% Zertifikat-Gewinn!
Am 13. April hatten wir den Abonnenten des RuMaS Express-Service einen Trade mit Axa vorgeschlagen. Im Text hatten wir deutlich gemacht, dass wir für diesen Trade ein Hebel-Zertifikat nehmen....